Answers are grounded in this paper and cite their sources.
Inflammatory bowel diseases frequently associated with oxidative stress phenomena represent an important component of intestinal inflammation. An excess of hydrogen peroxide (H2O2) is mucosa damaging, and its removal becomes a therapeutic strategy. The oral administration of antioxidant enzymes such as catalase remains challenging because enzyme activity can be rapidly impaired under gastric conditions. Carboxymethylcellulose (CMC)- and carboxymethylstarch (CMS)-based tablets for oral delivery of catalase were investigated. Tablets containing 30% (w/w) catalase were exposed for 2 h to simulated gastric fluid (SGF) followed by 5 h in simulated intestinal fluid (SIF). Approximately 58% of the initial catalase activity was recovered from the CMC-based tablets, and about 44% from the CMS-based tablets. Despite this partial recovery, both formulations retained sufficient functional activity to achieve near-complete degradation of 5 mM H2O2 in vitro within 240 min for CMC and 300 min for CMS. The incorporation of cross-linked starch improved the mechanical strength of the CMC-based tablets and maintained the percentage of catalase recovery. The association of catalase and probiotics within the same formulation was also examined. The co-formulated catalase–probiotics maintained bacterial viability following 2 h of gastric exposure and 5 h in SIF. The presence of catalase did not compromise the bacterial viability. It appears that such a system could provide a basis for future strategies simultaneously targeting intestinal oxidative stress and microbiota imbalance.
No takes yet. Share an insight, caveat, or question.
Dieye et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: